Merck KEYTRUDA Cuts Progression Risk By 43 % In Phase 3 Endometrial Cancer Trial

Source: rttnews.com · Section: business-tech · Bias: Center · Published: Tue, 27 Oct 2026 05:15:00 GMT

Published 10/27/2026